Drugs / TYRA-300-B01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06006702 | Oct 2023 → May 2025 overdue | — | Tyra Biosciences, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYRA-300-B01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06006702 ↗ |
| Action | Inhibit | “FGFR 3-selective tyrosine kinase inhibitor” NCT06006702 ↗ |
| Route | Oral | “TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor” NCT06006702 ↗ |